2.70
-0.08(-2.88%)
Currency In USD
| Previous Close | 2.78 |
| Open | 2.7 |
| Day High | 2.78 |
| Day Low | 2.68 |
| 52-Week High | 3.59 |
| 52-Week Low | 1.54 |
| Volume | 341,599 |
| Average Volume | 498,878 |
| Market Cap | 244.3M |
| PE | -9.31 |
| EPS | -0.29 |
| Moving Average 50 Days | 2.97 |
| Moving Average 200 Days | 2.36 |
| Change | -0.08 |
If you invested $1000 in Stereotaxis, Inc. (STXS) 10 years ago, it would be worth $2,812.5 as of November 05, 2025 at a share price of $2.7. Whereas If you bought $1000 worth of Stereotaxis, Inc. (STXS) shares 5 years ago, it would be worth $868.17 as of November 05, 2025 at a share price of $2.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025
GlobeNewswire Inc.
Oct 21, 2025 1:00 PM GMT
ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quar
Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs
GlobeNewswire Inc.
Oct 15, 2025 11:32 AM GMT
ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE Mark in Europe and submitted a 510(k) applicati
Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias
GlobeNewswire Inc.
Oct 13, 2025 11:34 AM GMT
ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus, Inc., a medical device company dedicat